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ABSTRACT
Objective: To assess the cost-effectiveness of rosuvastatin in
the treatment of hypercholesterolemia and the prevention of
ischemic heart disease (IHD) in Portugal.
Methods: A probabilistic Markov model was constructed to
analyze the costs and consequences of lifetime treatment with
rosuvastatin, atorvastatin, pravastatin, and simvastatin. For
this purpose, the results from randomized head-to-head trials
evaluating low-density lipoprotein (LDL) changes were com-
bined with the results from a meta-analysis deﬁning the rela-
tionship between LDL levels and fatal and nonfatal IHD
events. The incidence of myocardial infarction (MI) was
derived from a 9-year Portuguese observational study. The
eligible population was deﬁned as untreated individuals aged
more than 35 years with LDL levels above 115 mg/dl. Death
rates due to IHD and other causes were obtained from ofﬁcial
data. Resource use in the treatment of MI was estimated by
a Delphi panel of eight Portuguese cardiologists with at least
15 years of clinical practice. Costs were calculated from the
payers’ perspective.
Results: Rosuvastatin increases life expectancy between 5.5
and 12.1 days per patient. It is cost-saving when compared
to atorvastatin, but it increases costs when assessed against
pravastatin and simvastatin (€1,004 and €684 per patient,
respectively). Therefore, rosuvastatin is a dominant alterna-
tive compared to atorvastatin, having an incremental cost-
effectiveness ratio of €30,350 to pravastatin and €39,340 to
simvastatin. In the probabilistic sensitivity analysis, per-
formed rosuvastatin always dominates atorvastatin and is
associated with a cost per life-year gained inferior to
€50,000 in 95.7% of the cases when compared to pravas-
tatin and in 67.0% simulations when assessed against
simvastatin.
Conclusions: Rosuvastatin is a cost-effective alternative in
the prevention of IHD in Portugal.
Keywords: cost-effectiveness, ischemic heart disease, Portu-
gal, statins.
Introduction
Cardiovascular diseases (CVD) are the main cause of
death and a major morbidity factor around the world.
In 2002, 16.7 million people died of CVD [1]. In
Portugal, CVD is the main cause of death, accounting
for 38.4% of the number of deaths during 2002. It is
also the main cause of morbidity (evaluated by the
number of hospital admissions) [2]. CVD were respon-
sible for 6,862 disability-adjusted life-years lost per
100,000 inhabitants in 2000, 19% more than the
average in the richest European countries [3].
Coronary heart disease has several risk factors,
being the control of cholesterol levels highly important
for both primary and secondary prevention of fatal
and nonfatal events [4–9]. In fact, cholesterol reduc-
tion therapy has proved to be an effective instrument
of primary and secondary prevention in large-scale
clinical trials [10,11].
Some epidemiological studies were carried out to
assess lifestyle and the risk factors of CVD in Portugal.
A study carried out by the Portuguese Foundation of
Cardiology in 2002 showed that the prevalence of
high/very high risk of CVD was equal to 6.8% while
20.6% of the population had a moderate risk. A high
prevalence of some risk factors of CVD was found:
11.2% of the population were diabetic, 46.7%
suffered from hypercholesterolemia, 18.2% were
smokers, and 37.3% had systolic hypertension [12].
A recent study found that the Portuguese lipid
proﬁle in 2001 was as follows: total cholesterol
(TC) = 210.7 mg/dl (SD 42.9); low-density lipoprotein
(LDL) = 137 mg/dl (38.0), with 71.2% having an
LDL > 115 mg/dl; high-density lipoprotein (HDL) =
52.3 mg/dl (12.7), with only 3.1% being at risk
(HDL  35 mg/dl) [13]. This proﬁle shows high values
compared to what is desirable (as stated in the Euro-
pean guidelines [14]), indicating that the Portuguese
individuals could improve their lifestyle and increase
their consumption of lipid lowering drugs to prevent
ischemic heart disease (IHD). Within this framework,
Address correspondence to: Carlos Gouveia Pinto, R. Miguel
Lupi, 20, 1249-078 Lisboa, Portugal. E-mail: gpinto@iseg.utl.pt
10.1111/j.1524-4733.2007.00224.x
Volume 11 • Number 2 • 2008
V A L U E I N H E A LT H
154 © 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/08/154 154–159
the adoption of the most efﬁcacious drug is recom-
mended, but it is also important to choose the one that
provides the best value for money, because treatments
are lifelong and expensive.
Clinical data from a number of trials demonstrated
a superior efﬁcacy of rosuvastatin over atorvastatin,
pravastatin, and simvastatin, as assessed by a reduc-
tion in plasma LDL levels and the proportion of
patients achieving LDL goals [15–19]. Previous phar-
macoeconomic studies have shown that the superior
lipid-modifying effects of newer statins, such as atorv-
astatin, in comparison with older drugs are associated
with ﬁnancial beneﬁts [20,21]. The introduction of
rosuvastatin may represent an opportunity to gain
further efﬁcacy beneﬁts at an affordable cost.
In this article, the cost-effectiveness of rosuvastatin
compared to atorvastatin, pravastatin, and simvastatin
is assessed, as this accounts for almost 90% of the
statins market in Portugal. The article has the follow-
ing structure. First, we describe the methodology and
the data used. Next, the results for the base case are
presented, followed by the uncertainty analysis. In the
last section, we discuss the methods adopted and the
results obtained, and the main conclusions are drawn.
Methods and Data
The Model
A probabilistic Markov model was built to estimate the
incremental cost per life-year gained from the use of
rosuvastatin compared to atorvastatin, pravastatin,
and simvastatin, in the treatment of individuals aged
more than 35 years with previously untreated hyperc-
holesterolemia, using Microsoft Ofﬁce Excel 2003
(Microsoft, Redmond, WA). All patients were assumed
to start treatment with 10 mg of rosuvastatin and ator-
vastatin or with 20 mg of pravastatin or simvastatin,
with the dose being doubled if their LDL level exceeded
115 mg/dl after 12 weeks (no switch was allowed). The
LDL level is thenmeasured after another 12 weeks. The
LDL reduction achieved after 12 weeks (if LDL is below
115 mg/dl) or 24 weeks (if LDL is above 115 mg/dl
after 12 weeks) is assumed to remain stable thereafter
and determines the incidence of IHD events.
Available data indicate that the majority of patients
are treated with the initial doses assumed in this analy-
sis [22]. Use of statins with greater efﬁcacy in reducing
LDL levels may treat more patients to goal, using the
same starting dose, without the need for dose titration.
During each cycle, a patient may have a nonfatal
myocardial infarction (MI), a fatal MI, die due to other
causes, or remain in a nonevent state. Patients having
a nonfatal MI face a higher probability of dying during
the following cycle, because of the increased risk of
mortality in the 3 months after an MI [23]. The struc-
ture of the model is shown in Figure 1.
The eligible population is divided into 10 groups, as
ﬁve age groups (35–44; 45–54; 55–64; 65–74; and 75
and older) are deﬁned for both sexes. Whenever a
patient dies, his life expectancy (which depends on his
age/sex group) is counted as life-years lost by the
cohort to whom he belongs. The model allows for the
calculation of events occurring in 60 years’ time (260
cycles of 12 weeks), during which period all patients
are assumed to die.
Efﬁcacy of Statins and Their Impact on IHD Events
As the use of head-to-head trials decreases the poten-
tial for bias, efﬁcacy rates were obtained in trials in
which rosuvastatin was directly compared to atorvas-
tatin, pravastatin, or simvastatin. For the initial doses,
we used the results of a pooled analysis of ﬁve ran-
domized double-blind trials in patients with hypercho-
lesterolemia [15]. These trials were designed to allow
data pooling after 12 weeks of treatment and indicated
that rosuvastatin reduced LDL by 47.2%, atorvastatin
by 36.4%, pravastatin by 27.1%, and simvastatin by
35.7%. The patients who enrolled for the trials had an
LDL level of 160 and <250 mg/dl, triglycerides of
400 mg/dl, and an Eating Pattern Assessment Tool
score of 28.
As there are no 12-week clinical trials available for
20 mg doses of rosuvastatin and atorvastatin, we used
the results of Schneck et al. [16] over a 6-week ran-
domized double-blind trial. They concluded that
20 mg doses of rosuvastatin decreased LDL by 51.7%,
whereas 20 mg doses of atorvastatin reduced it by only
43.3% for patients with an LDL level of 160 and
<250 mg/dl, triglycerides of <400 mg/dl, an Eating
Pattern Assessment Tool score of 28, and without
active arterial disease in the previous 3 months. For
simvastatin and pravastatin 40 mg doses, LDL reduc-
tion was based on the Stellar trial [17]. Despite being
an open-label study, it is (to our knowledge) the only
trial that made a direct comparison of these ﬁxed doses
of simvastatin and pravastatin to rosuvastatin. Stellar
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Figure 1 Model structure.AMI, acute myocardial infarction; IHD, ischemic
heart disease.
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results indicate that simvastatin 40 mg decrease LDL
by 38.8% and that pravastatin diminish it by 29.7%
for patients with an LDL level of 160 and <250 mg/
dl, triglycerides of <400 mg/dl, and an Eating Pattern
Assessment Tool score of 28.
The impact of LDL on IHD events was derived from
a meta-analysis of 58 randomized trials carried out by
Law et al. [24]. The authors excluded trials without a
control group; trials during which the reduction of
LDL was too low (<0.2 mmol/L) or the IHD events too
few (<5); or trials that accounted for nonlipid IHD risk
factors. As it is generally accepted that the beneﬁts
obtained from statins are time-dependent, Law et al.
determined the relationship between IHD events and
LDL reduction for years 1, 2, 3–5, and 6 or more after
entry into the trial (Table 1). Furthermore, they found
a similar reduction in risk for fatal and nonfatal IHD
events, and for primary and secondary prevention.
Epidemiological Data
Portuguese data were used to estimate epidemiological
variables. Life expectancy and mortality rates due to
IHD and other causes were obtained from ofﬁcial
sources ([2] and [25], respectively). MI incidence rates
were based on the results of the “Médicos Sentinela”
project, which, from 1990 to 1998, studied the inci-
dence of MIs in patients followed in primary care
health centers [26]. Finally, the mortality rate during
the ﬁrst 3 months after an MI was derived from an
article by Gíria et al. [23].
The eligible population was deﬁned as patients with
LDL levels above 115 mg/dl, following the threshold
deﬁned in the European guidelines [14]. Cohort esti-
mates were based on the Becel study [13], the only
Portuguese study that quantiﬁed the LDL levels among
the population. Moreover, to avoid any bias in switch-
ing patterns between statins, we included only non-
treated individuals, who were assumed to be 20% of
the eligible population (according to the expert panel).
Economic Costs
Since IHD is a chronic condition, the price of the
largest pack of the most marketed brand of each statin
was used. So, the daily cost of rosuvastatin is €0.96
(10 mg) and €1.70 (20 mg), the price of atorvastatin is
€1.06 (10 mg) and €1.97 (20 mg), pravastatin costs
€0.75 (20 mg) and €1.02 (40 mg), and simvastatin
costs €0.74 (20 mg) and €1.49 (40 mg) [27].
Each fatal event was assumed to be costless and the
cost of an MI was valued as the sum of the diagnosis-
related group price and the costs of ambulatory care
after discharge. Since there are no published data on
the consumption of ambulatory care, this was esti-
mated by a Delphi panel of eight Portuguese cardiolo-
gists with at least 15 years of clinical practice. Unit
costs were based on ofﬁcial sources [27,28]. Costs
were assigned to the end of each cycle. This may under-
estimate them although not seriously as each cycle lasts
for only 12 weeks.
The estimated cost of an MI per patient was €5,450
during the ﬁrst 12 weeks and €279 for each subsequent
cycle from the societal perspective and €126 and €69
from the patients’ viewpoint. Resources include visits to
the doctor (including cardiologists, general practitio-
ners, and other specialists), adjuvant therapy, examina-
tions, and blood analysis (the authors will provide a
complete list of resource consumption upon request).
Only direct costs were computed, as it was impossible
to ﬁnd reliable estimates for productivity costs.
The discount rate applied to both costs and conse-
quences is 5%, as stipulated by the Portuguese guide-
lines for the economic evaluation of pharmaceuticals
[29].
Uncertainty
The model was run for 10,000 simulations to account
for uncertainty in the estimates of the parameters: we
used normal distributions for the eligible population
(percentage of the population with LDL levels of
115 mg/dl) and for the efﬁcacy of the drugs (mea-
sured by the absolute decrease on LDL level); log-
normal distributions for the relative risk associated
with the reduction of LDL; and beta distributions for
the incidence of MI and mortality rates. Also, a
uniform distribution in an interval of 20% was
assigned to follow-up costs (mainly adjuvant medica-
tions and laboratory tests). These were the only cost
items that were subject to uncertainty, as prices of
statins were ﬁxed and admission to hospital (and con-
sequent costs) necessarily followed each MI.
Results
Rosuvastatin allows for a slight increase in the
patients’ life expectancy. Hypercholesterolemic indi-
viduals treated with rosuvastatin live, on average,
5.5 days longer than those treated with atorvastatin;
12.1 days longer than patients using pravastatin, and
an extra 6.3 days than the ones taking simvastatin.
Since IHD incidence rates are higher for men than for
women, life-days gained for men are about 60%
higher than for women.
Table 1 Reduction in the risk of IHD events for a 1.0 mmol/L
decrease in the LDL level, according to the number of years in the
trial [24]
Years in the trial
% reduction in risk
Mean 95% CI
1st 11 [4–18]
2nd 24 [17–30]
3rd-5th 33 [28–37]
6th and subsequent 36 [26–45]
CI, conﬁdence interval; IHD, ischemic heart disease; LDL, low-density lipoprotein.
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Economic analyses demonstrate that rosuvastatin
produces savings when compared to atorvastatin
(€1,034 per patient) but increases costs if compared to
pravastatin (€1,004 per patient) or simvastatin (€684
per patient). These results are expected, as rosuvastatin
is cheaper than atorvastatin but more expensive than
pravastatin and simvastatin.
Considering costs and consequences (measured in
the number of life-years saved), rosuvastatin domi-
nates atorvastatin and implies an incremental cost-
effectiveness ratio per life-year gained of €30,350
against pravastatin and €39,340 when compared to
simvastatin.
Uncertainty Analysis
As the model was populated with stochastic variables,
it was possible to perform a probabilistic sensitivity
analysis [30]. Rosuvastatin is more effective than the
comparators in all simulations, with life-days gained
ranging from 4.3 to 17.4. It produces savings in all
simulations against atorvastatin, but is always
cost-increasing when compared to pravastatin or
simvastatin.
The cost-effectiveness acceptability curves, shown
in Figure 2, demonstrate that if the willingness to pay
for an additional life-year is above €76,589, rosuvas-
tatin will always be chosen. Moreover, they show that
rosuvastatin is a dominant alternative against atorvas-
tatin in all simulations and that, for a willingness to
pay of €50,000, rosuvastatin should be chosen in 96%
of the cases when compared to pravastatin and in 67%
of the situations against simvastatin.
Discussion and Conclusions
Lowering LDL levels has been shown to be beneﬁcial
in preventing IHD events: a 60 mg/dl decrease in LDL
has been equated to a reduction in the risk of IHD of
approximately 60% [24].
Our analysis has demonstrated the cost-effectiveness
of rosuvastatin compared to atorvastatin, as the former
was shown to be more efﬁcacious in reducing LDL
levels or treating patients to achieve LDL goals, and
less costly than the milligram-equivalent doses of
atorvastatin—even when adopting a conservative
economic approach, as no productivity costs were
accounted for. This analysis has also shown that, when
compared to either pravastatin or simvastatin, rosuvas-
tatin has a cost-effectiveness ratio inferior to €40,000.
Taken together with the results of several surveys,
which showed that many coronary patients were
under-treated and not achieving the LDL goal [31,32],
these ﬁndings strongly indicate that statin use should
be increased. Nevertheless, this would have a substan-
tial impact on health-care costs. As demonstrated in
the present study, the introduction of rosuvastatin
could be done at an affordable cost, allowing a greater
proportion of patients at risk to be treated to goal.
The superior efﬁcacy of rosuvastatin 10 mg dose
also means that fewer patients would need to be
titrated to a higher dose, thus avoiding the correspond-
ing costs.
Other factors not taken into account in this study
include the impact of statins on other lipid parameters,
such as the raising of HDL levels. As rosuvastatin has
been shown to promote greater increases in HDL
levels, compared to other statins, this may further con-
tribute toward improving cost-effectiveness. On the
other hand, a recent meta-analysis has demonstrated
that a decrease in LDL levels by 60 mg/dl reduces the
risk of strokes by 17%, preventing thromboembolic
but not hemorrhagic strokes [24].
The costs of managing adverse events were not
considered in this article, as it is assumed that the
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incidence and severity of adverse events were similar for
the four statins studied. In fact, when rosuvastatin was
introduced in the market, there were some concerns
about its safety [33,34] probably based on the previous
experience with cerivastatin [35]. Nevertheless, the
Food and Drug Administration has already published
information on its Web site stating that rosuvastatin is
as safe as other statins on the market [36] and the
American Journal of Cardiology recently published the
report of the National Lipid Association’s Statin Safety
Task Force in which several authors argued that the
incidence of adverse events with rosuvastatin is not
higher than with other statins [37]. Moreover, clinical
studies with rosuvastatin included more than 12,000
patients (which are more than four times the number of
patients included in any previous approval process with
statins) with around 4,000 patients consuming the
highest licensed dose (40 mg) [38].
In conclusion, this economic analysis has shown
that 10 mg doses of rosuvastatin are cost-effective in
treating patients with hypercholesterolemia to achieve
the guideline LDL goals, leading to a small gain in life
expectancy.
Source of ﬁnancial support: Research for this article was
supported by a grant from AstraZeneca and Medinfar, being
the latter a Portuguese pharmaceutical company. Indepen-
dence of the authors was guaranteed by a protocol signed by
all parties involved.
References
1 Mackay J, Mensah G. The Atlas of Heart Disease and
Stroke. Geneva: World Health Organization, 2004.
2 Direcção Geral da Saúde. Risco de Morrer em Portu-
gal 2001. Lisboa: DGS, 2003.
3 Gouveia M, Borges M, Costa J, Carneiro AV. Burden
of disease from hypercholesterolemia in Portugal. Rev
Port Cardiol 2004;23:255–70.
4 Castelli WP, Garrison RJ, Wilson PW, et al. Incidence
of coronary heart disease and lipoprotein cholesterol
levels. The Framingham Study. JAMA 1986;256:
2835–8.
5 Neaton JD, Wentworth D. Serum cholesterol, blood
pressure, cigarette smoking, and death from coronary
heart disease. Overall ﬁndings and differences by age
for 316,099 relation white men. Multiple Risk Factor
Intervention Trial Research Group. Arch Intern Med
1992;152:56–64.
6 Verschuren WM, Jacobs DR, Bloemberg BP, et al.
Serum total cholesterol and long-term coronary heart
disease mortality in different cultures. Twenty-ﬁve-
year follow-up of the seven countries study. JAMA
1995;274:131–6.
7 White AD, Hames CG, Tyroler HA. Serum cholesterol
and 20-year mortality in black and white men and
women aged 65 and older in the Evans County Heart
Study. Ann Epidemiol 1992;2:85–91.
8 Chen Z, Peto R, Collins R, et al. Serum cholesterol
concentration and coronary heart disease in popula-
tion with low cholesterol concentrations. BMJ
1991;303:276–82.
9 Ezzati M, Lopez AD, Rodgers A, et al., and the
Comparative Risk Assessment Collaborating Group.
Selected major risk factors and global and regional
burden of disease. Lancet 2002;360:1347–60.
10 Scandinavian Simvastatin Survival Study Group. Ran-
domised trial of cholesterol lowering in 4444 patients
with coronary heart disease: the Scandinavian Simv-
astatin Survival Study (4S). Lancet 1994;344:1383–9.
11 Pfeffer MA, Sacks FM, Moye LA, et al. Cholesterol
and recurrent events: a secondary prevention trial for
normolipidemic patients. Am J Cardiol 1995;76:C98–
106.
12 Santiago LM, Silva PS. Coronary heart disease risk:
the results of population screening by the central
region branch of the Portuguese heart foundation.
Rev Port Cardiol 2003;22:1039–48.
13 Instituto de Alimentação Becel. Estudo Epidemi-
ológico de Caracterização do Perﬁl Lipídico da Popu-
lação Portuguesa. Lisboa: Instituto de Alimentação
Becel, 2001.
14 De Backer G, Ambrosioni E, Borch-Johnsen K, et al.,
and The European Society of Cardiology Committee
for Practice Guidelines. European guidelines on car-
diovascular disease prevention in clinical practice:
third joint task force of European and other societies
on cardiovascular disease prevention in clinical prac-
tice (constituted by representatives of eight societies
and by invited experts). Eur J Cardiovasc Prev Rehabil
2003;10(Suppl.):S1–10.
15 Blasetto JW, Stein E, Brown W, et al. Efﬁcacy of rosu-
vastatin compared with other statins at selected start-
ing doses in hypercholesterolemic patients and in
special population groups. Am J Cardiol 2003;
91(Suppl.):C3–10.
16 Schneck DW, Knopp RH, Ballantyne CM, et al.
Comparative effects of rosuvastatin and atorvastatin
across their dose ranges in patients with hypercholes-
terolaemia and without active arterial disease. Am J
Cardiol 2003;91:33–41.
17 Jones PH, Davidson MH, Stein EA, et al. Comparison
of the efﬁcacy and safety of rosuvastatin versus ator-
vastatin, sinvastatin, and pravastatin across doses
(STELLAR Trial). Am J Cardiol 2003;92:152–60.
18 Davidson M, Ma P, Stein EA, et al. Comparison of
effects on low-density lipoprotein cholesterol and
high-density lipoprotein cholesterol with rosuvastatin
versus atorvastatin in patients with type IIa or IIb
hypercholesterolemia. Am J Cardiol 2002;89:268–75.
19 Schuster H, Barter PJ, Stenrer S, et al. Effects of
switching statins on achievement of lipid goals: mea-
suring effective reductions in cholesterol using rosuv-
astatin therapy (MERCURY I) study. Am Heart J
2004;147:705–12.
20 Huse DM, Russel MW, Miller JD, et al. Cost-
effectiveness of statins. Am J Cardiol 1998;82:1357–
63.
21 Elliott WJ, Weir DR. Comparative cost-effectiveness
of HMG-CoA reductase inhibitors in secondary
158 Pinto et al.
prevention of myocardial infarction. Am J Health Syst
Pharm 1999;56:1726–32.
22 IMS Health, IMS, Cognos, CD December 2006.
23 Gíria J, Catarino J, Rocha E. Acute coronary syn-
dromes and other forms of coronary heart disease in
the National Health Service, 1997–2001. Rev Port
Cardiol 2004;23:883–92.
24 Law MR, Wald NJ, Rudnicka AR. Quantifying effect
of statins on low density lipoprotein cholesterol,
ischaemic heart disease, and stroke: systematic review
and meta-analysis. BMJ 2003;326:1423–7.
25 Instituto Nacional de Estatística (INE). Estatísticas
Demográﬁcas 2003. Lisboa: INE, 2003.
26 Direcção Geral da Saúde, Projecto “Médicos Senti-
nela.” 2000. Available from: http://www.onsa.Part/
conteu/proj_ms_resul-estimativas_18_onsa.doc
[Accessed January 15, 2007].
27 Infarmed, Prontuário Terapêutico On-Line. 2007.
Available from: http://www.infarmed.Part/prontuario/
index.php [Accessed January 15, 2007].
28 Ministério da Saúde, Diário da República—I Série, n°
16 (Portaria n° 110-A/2007) de 23 de Janeiro de
2007.
29 Silva EA, Pinto CG, Sampaio C, et al. Orientações
Metodológicas para Estudos de Avaliação Económica
de Medicamentos. Lisboa: INFARMED, 1998.
30 Briggs A. Handling uncertainty in economic evalua-
tion and presenting the results. In: Drummond M,
McGuire A, eds. Economic Evaluation in Health
Care: Merging Theory with Practice. New York:
Oxford University Press, 2001.
31 EUROASPIRE II Study Group. Lifestyle and risk
factor management and use of drug therapies in coro-
nary patients from 15 countries: principal results from
EUROASPIRE II Euro Heart Survey Programme. Eur
Heart J 2001;22:554–72.
32 Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid
Treatment Assessment Project (L-TAP): a multicenter
survey to evaluate the percentages of dyslipidemic
patients receiving lipid-lowering therapy and achiev-
ing low-density lipoprotein cholesterol goals. Arch
Intern Med 2000;160:459–67.
33 Editorial. The statin wars: why AstraZeneca must
retreat. Lancet 2003;362:1341.
34 Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The
safety of rosuvastatin as used in common clinical
practice: a postmarketing analysis. Circulation 2005;
111:3051–7.
35 Bays H. Statin safety: an overview assessment
data—2005. Am J Cardiol 2006;97(Suppl. 1):S6–26.
36 Food and Drug Administration. Alert [03/2005].
Available from: http://www.fda.gov/cder/drug/
infopage/rosuvastatin/ [Accessed January 15, 2007].
37 McKenney JM. Introduction. Am J Cardiol 2006;
97(Suppl. 1);S1–2.
38 Jacobson T. Statin safety: lessons from new drug
applications for marketed statins. Am J Cardiol 2006;
97(Suppl. 1);S44–51.
Cost-Effectiveness of Rosuvastatin in Portugal 159
